OPENING SESSION

ESMO 2017

IN PARTNERSHIP WITH THE EACR

8-12 SEPTEMBER 2017
MADRID SPAIN
Fortunato Ciardiello
ESMO and Congress President
ONE DREAM …

23,000 participants

131 countries represented
ESMO: 42 YEARS OF EXCELLENCE

1975-1984
THE AUDACIOUS FIRST STEPS
OF A PIONEERING SOCIETY

1985-1994
COMMITTED TO
ONCOLOGY EDUCATION

1995-2004
UNIFYING ONCOLOGY
THROUGHOUT EUROPE

2005-2017
THE GLOBAL HOME FOR
ONCOLOGY PROFESSIONALS

ACROSS ONCOLOGY. WORLDWIDE.
ESMO: a member-centric society
ESMO STAFF
Anton Berns
EACR President
Prof. Dr. Anton Berns PhD
EACR President

Director Emeritus
Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital
Amsterdam, The Netherlands
About the EACR

- Established in 1968
- Over 10,000 members in 101 countries
- 14 affiliated National Societies (ASEICA etc.)

VISION

Science drives prevention and cures of cancer.

MISSION

EACR galvanises excellence in multidisciplinary cancer research by:
- Fostering interactions between researchers
- Organising cutting edge scientific meetings
- Educating the next generation of cancer scientists
- Campaigning for cancer research with funders, policy-makers and society
Members stats

Would you recommend EACR membership to others? 98% said ‘Yes’

Level of seniority

- Senior-level scientist: 14%
- Principal investigator/team leader: 25%
- Postdoc > four years since PhD: 12%
- Postdoc < four years since PhD: 14%
- Student: 24%
- Industry: 11%

Where do members work?

- University department: 63%
- Cancer research centre/institute: 33%
- Hospital: 18%
- Clinical research: 20%
- Translational research: 53%
- Epidemiology: 4%
- Medical doctor: 11%
- Other: 5%

Which areas do members work in?

*Participants could select multiple options*

*Information from the members’ survey January 2017*
Complementarity with ESMO

• Cancer research is a two-way street: Bench < ------ > Bedside. Increasingly information from clinical trials lead to new basic research questions.

• Interaction between scientists along this trajectory is key for accelerating progress.

• Fostering this interaction, learning each others language, and jointly formulating new research questions, is what we aspire to in the ESMO –EACR partnership.

• We are working to the same goal: improving prevention, diagnosis, and treatment of cancer.

• By working together we will make progress faster.
Miguel Martín Jiménez
ESMO 2017 Local Officer
ESMO 2017 LOCAL OFFICER ADDRESS

Prof. Miguel Martín Jiménez
ESMO 2017 Local Officer

Madrid, 8 September 2017
SEOM (Spanish Society of Medical Oncology), which I have the honor of presiding, is a National Scientific society in close collaboration with ESMO.

SEOM has 2,352 members.

1,283 Board-certificated Spanish Medical Oncologists are actually working in Spain.

378 Spanish Oncologists are members of ESMO and this number is increasing each year.

79 Medical Oncology Services are accredited for training residents in Medical Oncology in our country.
43 Spanish speakers in ESMO2017 (8% of total speakers)

150 Spanish abstracts accepted in ESMO2017 (5% of total abstracts)

23,000 total attendees to ESMO2017 (1,300 are Spanish)

130 Origin countries of attendees to ESMO2017
Underground

http://www.planometromadrid.org

Line 8-Estación Feria de Madrid

Bus lines:

• Line 112-Feria de Madrid - Bº Aeropuerto.
• Line 122-Avda. de América-Feria de Madrid.
• Line 828-Universidad Autónoma-Alcobendas-Feria de Madrid.
WELCOME TO MADRID!
Alberto Sobrero
ESMO Scientific Co-Chair
ESMO SCIENTIFIC ADDRESS

Alberto Sobrero
ESMO 2017 Scientific Co-Chair

Madrid, 8 September 2017
ESMO 2017 SCIENTIFIC ADDRESS

Alberto Sobrero
ESMO 2017 Scientific Co-Chair

Madrid, 8 September 2017
ESMO 2017 Scientific Steering Committee

ESMO 2017 and Congress President
Fortunato Ciardiello, Naples, Italy

ESMO 2017 Scientific Committee Co-Chairs
ESMO: Alberto Sobrero, Genoa, Italy
EACR: Richard Marais, Manchester, UK

ESMO 2017 Educational Chair
Andrés Cervantes, Valencia, Spain

ESMO 2017 Local Officer
Miguel Martín Jiménez, Madrid, Spain

ESMO 2017 Press Officer
Solange Peters, Lausanne, Switzerland
ESMO 2017 SCIENTIFIC COMMITTEE TRACK CHAIRS

**Basic science:** Anton Berns, Amsterdam, Netherlands and Christof von Kalle, Heidelberg, Germany; **Breast cancer, early stage:** Nadia Harbeck, Munich, Germany; **Breast cancer, metastatic:** Fabrice André, Villejuif, France; **CNS tumours:** Michael Weller, Zurich, Switzerland; **Developmental therapeutics:** Jan Schellens, Amsterdam, Netherlands; **Gastrointestinal tumours, colorectal:** Volker Heinemann, Munich, Germany; **Gastrointestinal tumours, non-colorectal:** Eric Van Cutsem, Leuven, Belgium; **Genitourinary tumours, prostate:** Johann de Bono, Sutton, UK; **Genitourinary tumours, non-prostate:** Bernard Escudier, Villejuif, France; **Gynaecological cancers:** Domenica Lorusso, Milan, Italy; **Haematological malignancies:** Mariano Provencio, Madrid, Spain; **Head and neck cancer:** Jean-Pascal Machiels, Brussels, Belgium; **Immunotherapy of cancer:** Inge Marie Svane, Herlev, Denmark; **Melanoma and other skin tumours:** Reinhard Dummer, Zurich, Switzerland; **NETs and endocrine tumours:** Michel Ducreux, Villejuif, France; **Non-metastatic NSCLC and other thoracic malignancies:** Pilar Garrido, Madrid, Spain; **NSCLC, metastatic:** Rafał Dziadziuszko, Gdansk, Poland; **Public health and health economics:** Paolo G. Casali, Milan, Italy; **Sarcoma:** Jean-Yves Blay, Lyon, France; **Supportive and palliative care:** Matti Aapro, Genolier, Switzerland; **Translational research:** Charles Swanton, London, UK (ESMO) and Joan Seoane, Barcelona, Spain (EACR); **ESMO Patient Advocacy Working Group:** Bettina Ryll, Uppsala, Sweden; **ESMO Young Oncologists Committee:** Matthias Preusser, Vienna, Austria

Representing approx. 280 Scientific Committee members across the 21 tracks
incl. 40 Educational Committee members on behalf of the full ESMO Faculty
THE MOST EXCITING ESMO CONGRESS EVER

❖ Four full days of Congress Programme
❖ Up to twelve sessions in parallel
❖ Three Presidential sessions, one each on Saturday, Sunday and Monday, presenting 7 Late-Breaking Abstracts (LBA) and 3 important practice-changing non-LBAs
❖ More than 520 invited speakers
❖ Programme content with high-quality content for all oncology professionals
Three Keynote lectures

Four full Award lectures

16 Joint Symposia and 13 ad-hoc Special interest sessions

Extended Young Oncologist programme including new Mentor sessions

Full sessions across 21 tracks

56 Industry satellites, including 2 ESMO Colloquia

Full Patient Advocacy track over 4 days

NOT-TO-MISS!
CLINICAL TRIALS REPRESENTED

Phase I: 101
Phase I/II: 39
Phase II: 177
Phase II/III: 4
Phase III: 161
ESMO 2017: LATE-BREAKING ABSTRACTS NOT TO MISS

**LBA2_PR**
Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

**LBA4_PR**
RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

**236O_PR**
MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

**928O_PR**
Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT)

**LBA7_PR**
BRIM8: A randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence

**LBA6_PR**
COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma

**LBA8_PR**
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

**LBA5**
CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups
SCIENTIFIC AND EDUCATIONAL PROGRAMME AT A GLANCE

Educational: 46 sessions
25% of programme

Scientific: 146 sessions
75% of programme

Abstract related, 51
Non-abstract related, 95
ESMO 2017 EDUCATIONAL PROGRAMME

46 sessions
25% of programme

- Educational sessions 23
- Challenge your expert 21
- Clinical Practice Guidelines 2
ESMO 2017 SCIENTIFIC PROGRAMME

146 sessions – 75% of the programme

Non-abstract related

- Keynote sessions, 3
- Multidisciplinary patient cases, 18
- Young Oncologists sessions, 8
- Controversy sessions, 5
- Patient Advocacy sessions, 9
- Special Symposia, 21
- Joint symposia, 16
- Ad-hoc special sessions, 13
- Congress Highlights, 2

Non-abstract related

- Presidential Symposia, 3
- Proffered paper sessions, 24
- Poster discussion sessions, 20
- Combined PP/PD session, 1
- Poster sessions, 3
ESMO 2017 ABSTRACT SUBMISSION

3,260 submitted, 1'736 accepted

Regular abstracts: 1,681

- Oral presentation: 82
- Poster discussion: 202
- Poster display: 1,397

Late-breaking abstracts: 55

- Oral presentation: 37
- Poster discussion: 18
ESMO 2016 Copenhagen
55 slots

ESMO 2017 Madrid
56 slots

Monday, 14 incl 1 Colloquium
Saturday, 14
Tuesday, 15
Friday, 12 incl 1 Colloquium

Monday, 14 incl 1 Colloquium
Friday, 12
Saturday, 15
Sunday, 15 incl 1 Colloquium

SATELLITE SYMPOSIA / ESMO COLLOQUIA
Thank you and have a great Congress experience!
Richard Marais
EACR Scientific Co-Chair
EACR SCIENTIFIC ADDRESS

Professor Richard Marais
EACR Scientific Co-Chair

Madrid, 8 September 2017
Cases

14.1 million

New cases of worldwide cancer, 2012

Common cancers

42%

More than 4 in 10 of new cases of cancer are lung, female breast, bowel or prostate cancer, 2012, worldwide

Projection to 2030

+68%

Cancer incidence rates projected increase 2012-2030, worldwide
THANK YOU!
THANK YOU!

Jean-Charles Soria
Annals of Oncology Editor-in-Chief
ESMO AWARD 2017
Miguel Martín Jiménez

President of the Spanish Society of Medical Oncology (SEOM)

Professor of Medicine at the Complutense University, Madrid, Spain

Head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañón, in Madrid, Spain